Holly Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.50 M
- Revenue Growth 27.77%
- Profit Growth -25.78%
- Ebitda 9.51%
- Net Worth 8.44%
- Total Assets 7.95%
About Holly Drugs
Holly Drugs Private Limited (HDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 18 July 2007 and has a history of 17 years and six months. Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.50 M.
Deepak Batra and Sahil Batra serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232CH2007PTC030879
-
Company No.
030879
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Jul 2007
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Holly Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Batra
|
Director | 18-Jul-2007 | Current |
|
Sahil Batra
|
Director | 25-Mar-2018 | Current |
Financial Performance of Holly Drugs.
Holly Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 27.77% increase. The company also saw a substantial fall in profitability, with a 25.78% decrease in profit. The company's net worth moved up by a moderate rise of 8.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Holly Drugs?
In 2022, Holly Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.50 M
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 0.40 Cr
- State Of India : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Aug 2013 | Indian Bank | ₹4.00 M | Open |
| 26 Nov 2007 | State Of India | ₹2.50 M | Open |
How Many Employees Work at Holly Drugs?
Unlock and access historical data on people associated with Holly Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Holly Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Holly Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
